Clinical trials in Valenciennes

106 clinical trials in Valenciennes, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Valenciennes at a glance

106

clinical trials

Paediatric trials0
Research sites1

Quick filters

106 trials in Valenciennes

Open in trial search

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

France

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Chronic kidney disease

Recruiting

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug

France

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Small cell lung cancer

Recruiting

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Topotecan Hydrochloride
Sponsor:Zai Lab (US) LLC

Contact Research Centre

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

France

Participants:18–64 years · 65+ years
Substances:Zilebesiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo

France

Participants:18–64 years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

France

Participants:18–64 years · 65+ years
Substances:Laroprovstat
Sponsor:AstraZeneca AB

Contact Research Centre

Sjogren's syndrome

Recruiting

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Emtricitabine
Sponsor:Novartis Pharma AG

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer stage IIIA+2

Recruiting

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hepatitis alcoholic

Recruiting

Study of N-acetylcysteine and prednisolone combination versus extended prednisolone treatment in patients with severe alcoholic hepatitis

Registered drug

Study of N-acetylcysteine and prednisolone combination versus extended prednisolone treatment in patients with severe alcoholic hepatitis

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Acetylcysteine
Sponsor:Centre Hospitalier Universitaire De Lille

Contact Research Centre

Cryoglobulinaemia

Recruiting

Study of obinutuzumab treatment for patients with non-infectious cryoglobulinemia vasculitis who did not respond to or cannot tolerate rituximab

Registered drugNo placebo

Study of obinutuzumab treatment for patients with non-infectious cryoglobulinemia vasculitis who did not respond to or cannot tolerate rituximab

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Heart failure with reduced ejection fraction

Recruiting

Study of Omecamtiv Mecarbil for Treating Patients with Chronic Heart Failure and Severely Reduced Heart Pumping Ability

Investigational

Study of Omecamtiv Mecarbil for Treating Patients with Chronic Heart Failure and Severely Reduced Heart Pumping Ability

Investigational

France

Participants:18–64 years · 65+ years
Substances:Omecamtiv mecarbil
Sponsor:Cytokinetics Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 379 cities in France

Clinical research in Valenciennes

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, including studies for both triple-negative and hormone receptor-positive variants. Research extends to lung cancer and pancreatic adenocarcinoma, evaluating novel therapeutic combinations.

Advanced breast cancer therapies
Non-small cell lung cancer treatments
Pancreatic cancer interventions

Trials are exploring immunotherapy combinations and targeted treatments to improve patient outcomes.

02 Cardiovascular Studies

Comprehensive research into cardiovascular disease management, with particular focus on stroke prevention and atherosclerosis. Studies evaluate new approaches for treating atrial fibrillation and reducing major cardiovascular events.

Lipoprotein management
Stroke prevention therapies
Heart failure treatments

Innovative treatments targeting both established cardiovascular disease and preventive care.

03 Autoimmune Conditions

Studies investigating treatments for various autoimmune disorders, including vasculitis and Crohn's disease. Research focuses on novel therapeutic approaches using targeted biological agents.

Vasculitis treatments
Inflammatory bowel disease therapies
Immunotherapy applications

Trials aim to improve remission rates and long-term disease management outcomes.

Back to France All countries